Autopsy report · NCT01438112

Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer

“Change in study design”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years 6 months before it started.
• Ran for about 2 years 3 months before it stopped.
• 22 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2, Phase 3

Sponsor

CG Oncology, Inc.

Sponsor type

Industry

Conditions

Transitional Cell Carcinoma; Bladder Cancer; Carcinoma in Situ; Carcinoma in Situ Concurrent With Papillary Tumors

Interventions

CG0070 Adenovirus Vector; Control Arm: Quadruple Choice

Participants

22

Sites

7

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.